Klin Farmakol Farm. 2012;26(1):29-37

Antidepressants - from theory to clinical use

Michaela Fujáková, Miloslav Kopeček
Psychiatrické centrum Praha, 3. lékařská fakulta Univerzity Karlovy, Praha

Antidepressants were first introduced to the market nearly 60 years ago. They were initially used to treat depression; however, their potential

is currently much broader. The development of biochemical, molecular and cellular techniques to investigate their mode of action helped us

to identify the etiology of many other psychopathological processes. In addition to the theoretical knowledge, the clinical usage, possible

adverse effects, drug-to-drug interactions as well as indications in specific population groups are discussed in the article.

specific population.

Keywords: antidepressants, mechanism of action, interactions and combinations, adverse effects, overdose and discontinuation,

Published: April 24, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fujáková M, Kopeček M. Antidepressants - from theory to clinical use. Klin Farmakol Farm. 2012;26(1):29-37.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kopeček M. Preskripce psychofarmak a jejich ceny v ČR v letech 2003,2005 a 2008, Čes a slov Psychiat 2010; 106(2): 119-120.
    2. Meller H, Malley J. Hydrazine derivatives of pyridinecarboxylic acids. Monatsschr Psychiatr Neurol. 1912; 33: 400.
    3. Selikoff IJ, Robitzek EH, Ornstein GG. Treatment of pulmonary tuberculosis with hydrazine derivatives of isonicotinic acid. JAMA. 1952; 150: 973-980. Go to original source... Go to PubMed...
    4. Smith JA. The use of the isopropyl derivative of isonicotinylhydrazine (Marsilid) in the treatment of mental disease. Am Pract. 1953; 4: 519-520.
    5. Kamman GR, Freeman JG, Lucero RJ. The effect of 1-isonicotinyl-2-isopropyl hydrazide (IIH) on the behaviour of longterm mental patients.J Nerv Ment Dis. 1953; 118: 391-407. Go to original source... Go to PubMed...
    6. Stein L. Effects and interactions of imipramine, chlorpromazine, reserpine and amphetamine on self-stimulation: possible neurophysiological basis of depression. Recent Adv Biol Psychiatry. 1961; 4: 288-309. Go to original source...
    7. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 1996; 29(1): 2-11. Go to original source... Go to PubMed...
    8. Simson PE, Weiss JM. Altered activity of the locus coeruleus in an animal model of depression. Neuropsychopharmacology. 1988; 1(4): 287-295. Go to PubMed...
    9. Gamo NJ, Arnsten AF. Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders. Behav Neurosci. 2011; 125(3): 282-296. Go to original source... Go to PubMed...
    10. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C. Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability. Neuropsychopharmacology. 1996; 15(5): 465-474. Go to original source... Go to PubMed...
    11. Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007; 12(4): 331-59. Epub 2007 Jan 16. Go to original source... Go to PubMed...
    12. Thase ME. Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci. 2006; 8(2): 217-226. Go to original source...
    13. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007; 64(3): 327-337. Go to original source... Go to PubMed...
    14. Devanand DP, Bowers MB Jr, Hoffman FJ Jr, Nelson JC. Elevated plasma homovanillic acid in depressed females with melancholia and psychosis. Psychiatry Res. 1985; 15(1): 1-4. Go to original source... Go to PubMed...
    15. Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Evoniuk G, Ratti E. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and activecontrolled clinical trials. J Psychopharmacol. 2011. Go to original source... Go to PubMed...
    16. Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2012 Jan; 46(1): 64-71. Go to original source... Go to PubMed...
    17. Howland RH. Vilazodone: another novel atypical antidepressant drug. J Psychosoc Nurs Ment Health Serv. 2011; 49(3): 19-22. doi: 10.3928/02793695-20110203-98. Epub 2011 Feb 16. Go to original source... Go to PubMed...
    18. Mnie-Filali O, Faure C, Lambás-Se?as L, El Mansari M, Belblidia H, Gondard E, Etiévant A, Scarna H, Didier A, Berod A, Blier P, Haddjeri N. Pharmacological blockade of 5-HT (7) receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology. 2011; 36(6): 1275-88. Epub 2011. Go to original source... Go to PubMed...
    19. Vidal R, Pilar-Cuéllar F, dos Anjos S, Linge R, Trece?o B, Vargas VI, Rodriguez-Gaztelumendi A, Mostany R, Castro E, Diaz A, Valdizán EM, Pazos A. New strategies in the development of antidepressants: towards the modulation of neuroplasticity pathways. Curr Pharm Des. 2011; 17(5): 521-533. Go to original source... Go to PubMed...
    20. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010; 25(3): 193-200. Go to original source... Go to PubMed...
    21. Švestka J, Mohr P. Agomelatin - antidepresivum s novým mechanizmem působení. Psychiatrie, časopis pro moderní psychiatrii, 2010; 14(2): 98-108.
    22. Tokita K, Yamaji T, Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav. 2012; 100(4): 688-704. Epub 2011 Apr 21. Go to original source... Go to PubMed...
    23. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011; 475(7354): 91-95. Go to original source... Go to PubMed...
    24. Yilmaz A, Schulz D, Aksoy A, Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav. 2002; 71(1-2): 341-344. Go to original source... Go to PubMed...
    25. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47(4): 351-354. Go to original source... Go to PubMed...
    26. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8): 856-864. Go to original source... Go to PubMed...
    27. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008; 63(4): 349-352. Go to original source... Go to PubMed...
    28. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res. 2011; 224(1): 107-11. Epub 2011 Jun 6. Go to original source... Go to PubMed...
    29. Jourdi H, Hsu YT, Zhou M, Qin Q, Bi X, Baudry M. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci. 2009; 29(27): 8688-8697. Go to original source... Go to PubMed...
    30. Takei N, Inamura N, Kawamura M, Namba H, Hara K, Yonezawa K, Nawa H. Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J Neurosci. 2004; 24(44): 9760-9769. Go to original source... Go to PubMed...
    31. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology. 2012; 62(1): 35-41. Epub 2011 Sep 2. Go to original source... Go to PubMed...
    32. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010; 67(5): 432-438. Epub 2010 Jan 15. Go to original source... Go to PubMed...
    33. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79(1): 103-113. Go to original source... Go to PubMed...
    34. Preskorn SH, Borges S, Flockhart D. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I. J Psychiatr Pract. 2006; 12(4): 244-249. Go to original source... Go to PubMed...
    35. Szegedi A, Wetzel H, Leal M, Härtter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry. 1996; 57(6): 257-264.
    36. de la Gándara J, Agüera L, Rojo JE, Ros S, de Pedro JM. Use of antidepressant combinations: which, when and why? Results of a Spanish survey. Acta Psychiatr Scand Suppl. 2005; (428): 32-36. Go to original source... Go to PubMed...
    37. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010; 167(3): 281-288. Epub 2009 Dec 15. Go to original source... Go to PubMed...
    38. Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001; 103(1): 66-72. Go to original source... Go to PubMed...
    39. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ. STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006 Mar 23; 354(12): 1243-1252. Go to original source... Go to PubMed...
    40. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009; 30(11): 3719-3735. Go to original source... Go to PubMed...
    41. Cerqueira JJ, Mailliet F, Almeida OF, Jay TM, Sousa N. The prefrontal cortex as a key target of the maladaptive response to stress.J Neurosci. 2007; 27(11): 2781-2787. Go to original source... Go to PubMed...
    42. Conrad CD, LeDoux JE, Magari?os AM, McEwen BS. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. Behav Neurosci. 1999; 113(5): 902-913. Go to original source... Go to PubMed...
    43. Radley JJ, Rocher AB, Janssen WG, Hof PR, McEwen BS, Morrison JH. Reversibility of apical dendritic retraction in the rat medial prefrontal cortex following repeated stress. Exp Neurol. 2005; 196(1): 199-203.
    44. Norrholm SD, Ouimet CC. Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. Synapse. 2001; 42(3): 151-163. Go to original source... Go to PubMed...
    45. Hajszan T, Dow A, Warner-Schmidt JL, Szigeti-Buck K, Sallam NL, Parducz A, Leranth C, Duman RS. Remodeling of hippocampal spine synapses in the rat learned helplessness model of depression. Biol Psychiatry. 2009; 65(5): 392-400. Go to original source... Go to PubMed...
    46. Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA, Almeida OF, Sousa N. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry. 2009; 14(8): 764-773. Go to original source... Go to PubMed...
    47. White N, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 2008; 4: 238-250. Go to original source... Go to PubMed...
    48. Buckley NA, McManus PR. Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325: 1332-1333. Go to original source... Go to PubMed...
    49. Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clinical Toxicology, 2007; 45: 315-332. Go to original source... Go to PubMed...
    50. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors in overdose. Journal of Toxicology. Clinical Toxicology, 2004; 42: 277-285. Go to original source... Go to PubMed...
    51. Ostrom M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram. Lancet, 1996; 348: 339-340. Go to original source... Go to PubMed...
    52. Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, Eklundh G. Symptoms and signs of sever citalopram overdose. Lancet, 1997; 349: 1602. Go to original source... Go to PubMed...
    53. Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose Br J Psychiatry. 2010; 196(5): 354-358. Go to original source... Go to PubMed...
    54. Kumar VV, Isbister GK, Duffull SB. The effect of decontamination procedures on the pharmacodynamics of venlafaxine in overdoseBr J Clin Pharmacol. 2011; 72(1): 125-132. doi: 10.1111/j.1365-2125.2011.03934.x. Go to original source... Go to PubMed...
    55. Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010; 167(8): 934-41. Epub 2010 May 17. Go to original source... Go to PubMed...
    56. Fabian TJ, Amico JA, Kroboth PD, Mulsant BH, Corey SE, Begley AE, Bensasi SG, Weber E, Dew MA, Reynolds CF, 3rd, Pollock BG. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004; 164(3): 327-332. Go to original source... Go to PubMed...
    57. Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H, Lapeyre-Mestre M, Schmitt L, Montastruc JL. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol. 2011 Nov 25. Go to original source... Go to PubMed...
    58. Gribbin J, Hubbard R, Gladman J, Smith C, Lewis S. Serotonin-norepinephrine reuptake inhibitor antidepressants and the risk of fallsin older people: case-control and caseseries analysis of a large UK primary care database. Drugs Aging. 2011; 28(11): 895-902. Go to original source... Go to PubMed...
    59. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011: 343.
    60. Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N, Colucci R, Corona T, Blandizzi C, Del Tacca M. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther. 2009; 31(1): 1426-1453. Go to original source... Go to PubMed...
    61. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005; 293(19): 2372-2383. Go to original source... Go to PubMed...
    62. Mohr P, Hnídek D, Hanka J, Čermák J, Bravermanová A, Melicher T. Psychofarmaka v těhotenství a laktaci, Postgraduální medicína, 01/2012, str. 17-23.
    63. Simon GE, Savarino J, Opersakalski B, et al. Suicide Risk During Antidepresant Treatment. Am J Psychiatry, 2006; 163(1) 41-47. Go to original source... Go to PubMed...
    64. Uhlíková P. Dětská a dorostová psychiatrie, Postgraduální medicína, 02/2011, str. 209-212.
    65. http://pdsp.med.unc.edu/pdsp.php.
    66. Bazire S. Psychotropic drug directory, LloydReinhold Communications, Warwickshire, UK, 2012.
    67. Tadic, Lieb K. Pharmakotherapie bei therapieresistenter Depression. Nervenartz, 2007(Suppl 3); 78: 551-564. Go to original source... Go to PubMed...
    68. Food and Drug Administration Safety Communication. Chantix (Varenicline) Drug Label now contains Updated Efficacy and Safety Information. http://www.fda.gov/Drugs/DrugSafety/ucm264436.htm.
    69. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927. Go to original source... Go to PubMed...
    70. Derijks HJ, Heerdink ER, Janknegt R, De Koning FHP, Olivier B, Loone AJM, Egberts A, CG. Visualizing pharmacological activites of antidepressant: A novel approach. The Open Pharmacology Journal, 2008; 2: 54-62. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.